June 25, 2021 | Featured
FabRx Ltd., the renowned biotechnology start-up that launched the pharmaceutical 3D printer M3DIMAKER™, and Gustave Roussy, French Cancer-Research Institute recognised as the best oncology hospital in Europe, today announced their new research collaboration. The collaboration aims to develop novel, personalised, multi-drug dosage forms for the treatment of early-stage breast cancer patients. Anticancer therapy will be combined with anti-side effect treatment into a single pill using 3D printing technology to improve adherence rates and patient wellbeing. This collaboration aims to push the boundaries of current pharmaceutical thinking and make clinically used, pharmaceutical 3D printing a reality.
Currently, medicines are produced using mass manufacturing methods, creating dosage forms with identical characteristics (dosage, appearance and drug release). A major limitation of this one-size-fits-all approach is that each patient is different and would benefit from accurate personalised doses and drug combinations. In addition, taking multiple pills every day and pre-preparing medication is cumbersome and can reduce adherence to treatment plans, reducing their effectiveness. Pharmaceutical 3D printing offers an accurate, efficient and cost-effective method to avoid these issues, by combining multiple drugs with personalised doses into a single pill. Pharmaceutical 3D printing also offers future opportunities for further personalisation of medication, including flavours, colours and shapes, improving treatment adherence in multiple patient groups.
For this collaboration, FabRx and Gustave Roussy will develop 3D-printable formulations of anticancer drugs and anti-side effect medications. The formulations will be printed using FabRx’s pharmaceutical 3D printer, M3DIMAKER™, as personalised, multi-drug dosage forms. Once developed, these novel medicines will be used in a multi-centre clinical study led by Gustave Roussy, assessing the effectiveness of these new medicines for improving acceptability, adherence and ultimately patient outcome compared to the standard treatment regime.
Figure: 3D printed tablets (Printlets) with different shapes, sizes, flavours and doses
Commenting on the collaboration, Dr. Alvaro Goyanes, Co-founder and Director of Development at FabRx said “This collaboration is a big step forward for the implementation of 3D printing technology into the clinic and will provide better medicines to cancer patients, personalised to their needs.”
Maxime Annereau, pharmacist leading this project at Gustave Roussy, and Dr. Barbara Pistilli, oncologist and Head of The Breast Pathology Committee at Gustave Roussy said “To reduce the risk of recurrence, many women with early-stage breast cancer are treated with hormone therapy for five years, often in combination with additional treatments to manage side effects. Taking all of these treatments in a single 3D printed tablet with a personalised dose should improve adherence to treatment. This collaboration will allow us to go even further in personalised medicine and offer our patients tailor-made anticancer medicines.”
This project is a part of the larger program INTERLACE led by Dr. Ines Vaz-Luis at Gustave Roussy. This program aims to change the paradigm of breast cancer survivorship care by focusing on personalising survivorship care through the development of new therapeutic tools.
Background on FabRx
FabRx Ltd. was established in 2014 by leading academics from University College London (UCL), Prof. Abdul Basit, Prof. Simon Gaisford and Dr Alvaro Goyanes, and is recognised as a world leader in the application of 3D printing technology for medicines and medical devices. FabRx’s founders have a wealth of experience in all aspects of pharmaceutical 3D printing, oral drug formulation and knowledge of the challenges of bringing new medicines through regulatory processes of the pharmaceutical sector. Since its initiation, FabRx has developed over seven different types of pharmaceutical 3D printers and in 2017 were awarded with the TCT Best Start Up Award. In 2019, FabRx conducted a world-first clinical study using 3D printed personalised doses, utilising their Printlets™ technology for paediatric patients with Maple Syrup Urine Disease, a rare metabolic disorder. Following a grant from Innovate UK totalling near £1 million, FabRx launched M3DIMAKER™ in early 2020, the world’s first personalised medicine 3D printer, developed with multiple integrated nozzles and fingerprint access control. Recently, FabRx won the Excellence in Pharma: Manufacturing Technology and Equipment Award at the prestigious CPhI Pharma Awards for the M3DIMAKER™.
Background on Gustave Roussy
Classed as the leading European Cancer Centre, Gustave Roussy is a hospital with comprehensive expertise and is devoted entirely to patients suffering with cancer. It is a source of diagnostic and therapeutic advances. Gustave Roussy caters for almost 50,000 patients per year and its approach is one that integrates research, patient care and teaching. It is specialised in the treatment of rare cancers and complex tumours and it treats all cancers in patients of any age. Care is personalised and combines the most advanced medical methods with an appreciation of the patient’s individual requirements. In addition to the quality of treatment offered, the physical, psychological and social aspects of the patient’s life are respected. 3,200 health professionals work on Gustave Roussy’s two campuses: Villejuif and Chevilly-Larue. Gustave Roussy brings together the essential skills required for the highest quality oncology research; a quarter of patients treated are included in clinical trials.
For further information: www.gustaveroussy.fr/en
Global press contacts:
29-39 Brunswick Square
London WC1N 1AX
Phone: +44 7454887793
Phone: +33 142 11 50 59
Copyright © 2021 FabRx Ltd